Saturn V Capital Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001964437

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2023 · 20 positions · Total reported value $238.93M · Top-10 concentration 71.7% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 42.3% · 3 new · 6 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -11.5% · vs SPY -13.6% · Prev Value $697.47M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.1% · vs SPY -6.3% · Latest Value $683.13M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2023 13F filing, Saturn V Capital Management LP disclosed 20 equity positions with a combined reported value of $238.93M. The filing implies a focused portfolio: its ten largest positions account for 71.7% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2023 were CRNX ($33.50M), KALV ($17.43M), COGT ($17.31M). By sector, the heaviest allocations are Health Care 56.2%, Other 43.8%.

Versus the prior quarter, Saturn V Capital Management LP opened 3 new positions, trimmed 6 and fully exited 2, a turnover rate of 42.3% of positions.

The largest new positions opened in Q3 2023 were CRNX ($33.50M), KALV ($17.43M), COGT ($17.31M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2023)

  • CRNX CRINETICS PHARMACEUTICALS IN · $33.50M
  • KALV KALVISTA PHARMACEUTICALS INC · $17.43M
  • COGT COGENT BIOSCIENCES INC · $17.31M
  • CBAY CYMABAY THERAPEUTICS INC · $16.77M
  • BIIB BIOGEN INC · $16.62M
  • AMLX AMYLYX PHARMACEUTICALS INC · $16.23M
  • CYTK CYTOKINETICS INC · $14.59M
  • SRPT SAREPTA THERAPEUTICS INC · $14.35M

Fully Exited (vs previous quarter)

No tracked position was fully exited this quarter.

Insider Transactions (Form 4)

Latest Saturn V Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Saturn V Capital Management LP, based in Austin, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 23 positions worth $697.47M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-128448 (status: Approved), registered 2023-07-27
  • Regulatory AUM (Form ADV): $793.21M as of 2026-08-04
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 3 hedge funds

Portfolio Structure

  • 23 positions · $697.47M reported value (Q2 2026)
  • Top 10 holdings = 75.6% of reported value
  • Largest position: AMLX (AMYLYX PHARMACEUTICALS INC) at 11.9%
  • Average position size: $30.32M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 12 added, 6 reduced, 1 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 56.2%
Other 43.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.13M $33.50M 14.02%
14.02%
New
2 1.81M $17.43M 7.30%
7.30%
New
3 1.78M $17.31M 7.25%
7.25%
New
4 1.12M $16.77M 7.02%
7.02%
New
5 64.68K $16.62M 6.96%
6.96%
New
6 886.14K $16.23M 6.79%
6.79%
New
7 495.17K $14.59M 6.11%
6.11%
New
8 118.40K $14.35M 6.01%
6.01%
New
9 111.05K $12.85M 5.38%
5.38%
New
10 807.97K $11.73M 4.91%
4.91%
New
11 994.76K $10.89M 4.56%
4.56%
New
12 112.47K $10.53M 4.41%
4.41%
New
13 577.10K $10.36M 4.34%
4.34%
New
14 109.69K $9.70M 4.06%
4.06%
New
15 1.22M $9.09M 3.81%
3.81%
New
16 982.46K $6.96M 2.91%
2.91%
New
17 10.07K $4.95M 2.07%
2.07%
New
18 136.74K $3.13M 1.31%
1.31%
New
19 1.39M $970.91K 0.41%
0.41%
New
20 40.07K $944.76K 0.40%
0.40%
New

FAQ

What did Saturn V Capital Management LP buy in 2023-Q3?

In its 2023-Q3 13F filing, Saturn V Capital Management LP reported 20 equity positions worth $238.93M in aggregate; its largest disclosed positions were CRNX ($33.50M), KALV ($17.43M), COGT ($17.31M).

How large is Saturn V Capital Management LP's portfolio?

Saturn V Capital Management LP reported $238.93M of long equity holdings across 20 positions as of 2023-Q3. Top-10 holdings account for 71.7% of reported value.

What is Saturn V Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/saturn-v-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →